BioTrends Research GroupPosted on:25 Oct 12 PharmiWeb.com (press release) Despite initial hesitancy to prescribe biosimilar monoclonal antibodies, the market opportunity for biosimilar versions of rituximab, trastuzumab, cetuximab, and bevacizumab are forecast to exceed $4.9 billion in 2021. “74-80 percent of surveyed US ... |
